• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Publication
Peer-Reviewed
Evidence-Based OncologyJanuary 2021
Volume 27
Issue 1

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

Related Videos
Dawn Klemow, MD, assistant clinical professor, The University of Texas Southwestern Medical Center
Mikael Eriksson, PhD.
Roberto Salgado, MD.
Komal Jhaveri, MD, FACP.
Mei Wei, MD.
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Mabel Mardones, MD.
Mei Wei, MD.
A panel of 4 experts on breast cancer
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.